Appeal No. 1995-2831
Application No. 07/908,376
We make reference to the examiner’s answer (Paper No. 18, mailed November 1, 1994) for the
examiner’s reasoning in support of the rejection and to the appellant’s brief (Paper No. 16, filed August
22, 1994) for the appellant’s arguments thereagainst.
THE INVENTION
Appellant’s claimed invention is directed to oligonucleotides which are conjugated to at least
one sugar phosphate moiety which is independent of a nucleotide unit (claim 53), a composition for
binding to an RNA, a DNA, a protein or a peptide which comprises the conjugated oligonucleotide
described in claim 53 and an acceptable pharmaceutical carrier (claim 54), and a probe for determining
the presence of a target DNA or RNA sequence which comprises the conjugated oligonucleotide
described in claim 53 (claim 55). Claims 9 and 26 specify selected sugar phosphate moieties. [Brief,
page 1, last paragraph - page 2, first full paragraph.]
OPINION
Lemaitre describes conjugates of a polypeptide (i.e., poly(L-lysine)) and an oligonucleotide
(i.e., antisense oligodeoxyribonucleotide sequence) used to deliver antisense sequences to intact cells,
thereby promoting a specific and efficient antiviral activity. Little is known about the pathway of their
internalization. Lemaitre states that oligonucleotide could conceivably be conjugated to other
polypeptides, thus allowing targeting of the conjugated sequences to cells bearing specific cell-surface
determinants. [Abstract; page 652.]
- 3 -
Page: Previous 1 2 3 4 5 6 7 8 9 Next
Last modified: November 3, 2007